{"nctId":"NCT02764801","briefTitle":"Contrast-enhanced Ultrasound Evaluation of Chemoembolization","startDateStruct":{"date":"2016-04"},"conditions":["Hepatocellular Carcinoma","Chemoembolization, Therapeutic"],"count":131,"armGroups":[{"label":"Contrast ultrasound arm","type":"EXPERIMENTAL","interventionNames":["Drug: Ultrasound contrast agent (Contrast-enhanced ultrasound)","Device: Logiq E9 Scanner (Contrast-enhanced ultrasound)"]}],"interventions":[{"name":"Ultrasound contrast agent (Contrast-enhanced ultrasound)","otherNames":["Definity (Lantheus Medical Imaging)","Microbubble contrast agent"]},{"name":"Logiq E9 Scanner (Contrast-enhanced ultrasound)","otherNames":["Ultrasound Scanner"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients \\>= 21 years of age\n* Patient capable of making informed decisions regarding his/her treatment\n* Scheduled for TACE treatment of a HCC mass (lesions reported as Liver Imaging Reporting and Data Systems 4B or 5 or Organ Procurement and Transplantation Network 5a or 5b)\n* Negative pregnancy test in a female of child-bearing age.\n* Have an HCC mass viewable on grayscale B-mode ultrasound.\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing.\n* Patients not eligible or scheduled for TACE of a HCC mass.\n* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h after their final CEUS exam.\n* Patients who have received prior radioembolization (Y90) of the lesion of interest.\n* Patients with known or suspected cardiac shunts.\n* Patients with pulmonary hypertension or unstable cardiopulmonary conditions.\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:\n* Patients with unstable occlusive disease (e.g., crescendo angina)\n* Patients with clinically unstable cardiac arrhythmias\n* Patients with uncontrolled congestive heart failure (NYHA Class IV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization","description":"The ability of contrast-enhanced ultrasound to detect residual disease (and thereby need for tumor re-treatment) will be determined 1-2 weeks post chemoembolization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization","description":"The ability of contrast-enhanced ultrasound to detect residual disease (and thereby need for tumor re-treatment) will be determined 1 month post chemoembolization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":103},"commonTop":["post-embolization syndrome","nausea/vomiting","IV infiltration"]}}}